Sage Therapeutics (NASDAQ:SAGE) PT Lowered to $17.00

Sage Therapeutics (NASDAQ:SAGE) had its price objective lowered by analysts at Oppenheimer from $25.00 to $17.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective would suggest a potential upside of 35.24% from the stock’s current price.

A number of other equities analysts have also commented on SAGE. JPMorgan Chase & Co. boosted their price target on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, March 26th. Wedbush restated a “neutral” rating and issued a $24.00 price target on shares of Sage Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “neutral” rating and set a $28.00 target price on shares of Sage Therapeutics in a research report on Wednesday. Morgan Stanley upped their target price on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Finally, TD Cowen reduced their target price on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $39.72.

Sage Therapeutics Stock Down 19.6 %

NASDAQ:SAGE opened at $12.57 on Thursday. The firm has a market cap of $755.58 million, a PE ratio of -1.39 and a beta of 0.86. Sage Therapeutics has a 12 month low of $10.92 and a 12 month high of $59.99. The company’s 50-day moving average price is $20.06 and its two-hundred day moving average price is $20.96.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. The firm had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company’s revenue for the quarter was up 2621.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.47) earnings per share. On average, research analysts expect that Sage Therapeutics will post -6.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its stake in Sage Therapeutics by 3.5% in the fourth quarter. Amalgamated Bank now owns 6,964 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 235 shares during the last quarter. Captrust Financial Advisors lifted its stake in Sage Therapeutics by 9.0% in the second quarter. Captrust Financial Advisors now owns 6,091 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 502 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Sage Therapeutics by 1.0% in the second quarter. Alliancebernstein L.P. now owns 61,100 shares of the biopharmaceutical company’s stock valued at $2,873,000 after acquiring an additional 600 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in Sage Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 15,278 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 698 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.